08:23 AM EDT, 07/17/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Thursday that a new drug application for TAR-200 to treat patients with a form of high-risk non-muscle invasive bladder cancer has received US Food and Drug Administration priority review.

The application is supported by a phase 2b study that showed an 82.4% complete response rate, with 52.9% of patients remaining cancer-free at least a year after achieving a complete response, the company said.

The company said that a majority of adverse reactions were mild and moderate, with no reported systemic adverse reactions.